应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DFTX Definium Therapeutics
盘后交易 07-14 19:03:46 EDT
45.98
+2.33
+5.34%
盘后
45.57
-0.41
-0.89%
18:57 EDT
最高
46.45
最低
43.00
成交量
141.67万
今开
43.48
昨收
43.65
日振幅
7.90%
总市值
59.77亿
流通市值
57.54亿
总股本
1.30亿
成交额
6,444万
换手率
1.13%
流通股本
1.25亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Definium Therapeutics盘中下跌5.44%,报44.47美元
行情直击 · 07-13 22:21
异动解读|Definium Therapeutics盘中下跌5.44%,报44.47美元
异动解读|Definium Therapeutics盘中下跌5.06%,报46.0美元
行情直击 · 07-10
异动解读|Definium Therapeutics盘中下跌5.06%,报46.0美元
异动解读|Definium Therapeutics盘中上涨5.09%,DT120三期临床成功叠加巨额融资提振市场信心
行情直击 · 07-09
异动解读|Definium Therapeutics盘中上涨5.09%,DT120三期临床成功叠加巨额融资提振市场信心
异动解读|Definium Therapeutics盘中下跌5.02%,报44.68美元
行情直击 · 07-01
异动解读|Definium Therapeutics盘中下跌5.02%,报44.68美元
异动解读|Definium Therapeutics盘中上涨5.04%,DT120三期临床积极叠加8亿美元增发落地提振信心
行情直击 · 06-30
异动解读|Definium Therapeutics盘中上涨5.04%,DT120三期临床积极叠加8亿美元增发落地提振信心
Definium Therapeutics 宣布完成8.05亿美元增发,承销商全额行使超额配售权
美股速递 · 06-26
Definium Therapeutics 宣布完成8.05亿美元增发,承销商全额行使超额配售权
异动解读|Definium Therapeutics盘中上涨9.07%,核心管线3期研究达成主要终点及7亿美元增发定价落地
行情直击 · 06-25
异动解读|Definium Therapeutics盘中上涨9.07%,核心管线3期研究达成主要终点及7亿美元增发定价落地
异动解读|Definium Therapeutics盘中上涨15.48%,核心管线3期研究达成主要终点叠加投行大幅上调目标价
行情直击 · 06-24
异动解读|Definium Therapeutics盘中上涨15.48%,核心管线3期研究达成主要终点叠加投行大幅上调目标价
Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元
金吾财讯 · 06-24
Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元
Definium Therapeutics公布DT120口崩片治疗重度抑郁症的3期EMERGE研究积极顶线结果
美股速递 · 06-22
Definium Therapeutics公布DT120口崩片治疗重度抑郁症的3期EMERGE研究积极顶线结果
Definium Therapeutics:DT120口崩片研究达成主要及所有关键次要疗效终点
美股速递 · 06-22
Definium Therapeutics:DT120口崩片研究达成主要及所有关键次要疗效终点
Definium Therapeutics将于2026年6月22日讨论重度抑郁症III期EMERGE研究的顶线结果
美股速递 · 06-22
Definium Therapeutics将于2026年6月22日讨论重度抑郁症III期EMERGE研究的顶线结果
Definium Therapeutics宣布在DT120 Odt针对重度抑郁症的第二个三期关键研究“Ascend”中完成首例患者给药
美股速递 · 05-12
Definium Therapeutics宣布在DT120 Odt针对重度抑郁症的第二个三期关键研究“Ascend”中完成首例患者给药
Definium Therapeutics 研发DT120口腔崩解片 针对广泛性焦虑症、重度抑郁症及其他严重脑健康疾病
美股速递 · 04-19
Definium Therapeutics 研发DT120口腔崩解片 针对广泛性焦虑症、重度抑郁症及其他严重脑健康疾病
Piper Sandler 首予 Definium Therapeutics 增持评级,目标价49美元
美股速递 · 04-10
Piper Sandler 首予 Definium Therapeutics 增持评级,目标价49美元
Definium Therapeutics现金储备雄厚:截至2025年底持有4.116亿美元现金及投资,预计可支撑运营至2028年
美股速递 · 02-27
Definium Therapeutics现金储备雄厚:截至2025年底持有4.116亿美元现金及投资,预计可支撑运营至2028年
加载更多
公司概况
公司名称:
Definium Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Definium Therapeutics, Inc.于2010年根据不列颠哥伦比亚省法律成立。他们是一家处于后期阶段的临床生物制药公司,正在开发新的候选产品来治疗大脑健康障碍。他们的使命是通过将科学的严谨性应用于迷幻药,锻造精神病学的新时代,目标是开发可获得的治疗方法,以大规模解锁愈合。他们正在开发一系列针对神经递质通路的创新候选产品,这些通路在大脑健康疾病中发挥着关键作用。
发行价格:
--
{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":45.98,"timestamp":1784059200000,"preClose":43.65,"halted":0,"volume":1416684,"hourTrading":{"tag":"盘后","latestPrice":45.57,"preClose":45.98,"latestTime":"18:57 EDT","volume":18330,"amount":841332.62928,"timestamp":1784069866008,"change":-0.41,"changeRate":-0.008917,"amplitude":0.022836},"delay":0,"changeRate":0.053379152348224476,"floatShares":125130818,"shares":130000000,"eps":-2.49367,"marketStatus":"盘后交易","change":2.33,"latestTime":"07-14 19:03:46 EDT","open":43.48,"high":46.45,"low":43,"amount":64439720.51262,"amplitude":0.079038,"askPrice":45.99,"askSize":1,"bidPrice":45.51,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-2.49367,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784073600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":43.65,"preHourTrading":{"tag":"盘前","latestPrice":43.54,"preClose":43.65,"latestTime":"09:29 EDT","volume":2138,"amount":94107.42666,"timestamp":1784035799999,"change":-0.11,"changeRate":-0.00252,"amplitude":0.038786},"postHourTrading":{"tag":"盘后","latestPrice":45.57,"preClose":45.98,"latestTime":"18:57 EDT","volume":18330,"amount":841332.62928,"timestamp":1784069866008,"change":-0.41,"changeRate":-0.008917,"amplitude":0.022836},"volumeRatio":0.562789,"impliedVol":1.1934,"impliedVolPercentile":0.8115},"requestUrl":"/m/hq/s/DFTX","defaultTab":"news","newsList":[{"id":"1111295043","title":"异动解读|Definium Therapeutics盘中下跌5.44%,报44.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111295043","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111295043?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:21","pubTimestamp":1783952499,"startTime":"0","endTime":"0","summary":"7月13日,Definium Therapeutics盘中下跌5.44%,报44.47美元/股,成交额1282.29万美元。Definium Therapeutics所在的制药行业中,个股中,礼来跌0.21%,辉瑞涨1.78%,强生涨0.03%,Crinetics Pharmaceuticals涨0.06%,阿斯利康跌1.47%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142071966","title":"异动解读|Definium Therapeutics盘中下跌5.06%,报46.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142071966","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142071966?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:51","pubTimestamp":1783691501,"startTime":"0","endTime":"0","summary":"7月10日,Definium Therapeutics盘中下跌5.06%,报46.0美元/股,成交额912.92万美元。Definium Therapeutics所在的制药行业中,个股中,礼来跌2.01%,强生涨0.17%,阿斯利康跌2.55%,Crinetics Pharmaceuticals涨0.05%,默沙东跌0.42%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143979950","title":"异动解读|Definium Therapeutics盘中上涨5.09%,DT120三期临床成功叠加巨额融资提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1143979950","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143979950?lang=zh_cn&edition=full","pubTime":"2026-07-09 23:53","pubTimestamp":1783612422,"startTime":"0","endTime":"0","summary":"7月9日,Definium Therapeutics盘中上涨5.09%,报47.625美元/股,成交额6690.95万美元。消息面上,公司此前公布其核心产品DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果,达到主要终点及所有关键次要疗效终点,安全性特征良好。RBC Capital随之将目标价由36美元大幅上调至57美元,维持\"跑赢大市\"评级。关键临床数据验证叠加充裕资金保障,持续推动股价上行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137042231","title":"异动解读|Definium Therapeutics盘中下跌5.02%,报44.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042231","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137042231?lang=zh_cn&edition=full","pubTime":"2026-07-01 23:49","pubTimestamp":1782920992,"startTime":"0","endTime":"0","summary":"7月1日,Definium Therapeutics盘中下跌5.02%,报44.68美元/股,成交额4259.27万美元。Definium Therapeutics所在的制药行业中,个股中,礼来跌0.61%,强生跌0.66%,辉瑞跌0.69%,默沙东跌1.49%,诺和诺德涨2.69%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142122370","title":"异动解读|Definium Therapeutics盘中上涨5.04%,DT120三期临床积极叠加8亿美元增发落地提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1142122370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142122370?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:03","pubTimestamp":1782828238,"startTime":"0","endTime":"0","summary":"6月30日,Definium Therapeutics盘中上涨5.04%,报48.84美元/股,成交额2163.95万美元。消息面上,公司近期利好密集释放。随后公司迅速启动增发融资,最终以每股34美元完成约2370万股的扩大规模公开发行,募资总额达8.05亿美元,承销商全额行使超额配售权,反映市场认购需求旺盛。此外,RBC Capital将公司目标价从36美元大幅上调至57美元,维持\"跑赢大盘\"评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160379075","title":"Definium Therapeutics 宣布完成8.05亿美元增发,承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1160379075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160379075?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:25","pubTimestamp":1782419116,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 公司已成功完成其增发规模达8.05亿美元的公开募股。此次发行规模较原计划有所扩大,并包含了承销商全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111531466","title":"异动解读|Definium Therapeutics盘中上涨9.07%,核心管线3期研究达成主要终点及7亿美元增发定价落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1111531466","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111531466?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:26","pubTimestamp":1782397562,"startTime":"0","endTime":"0","summary":"6月25日,Definium Therapeutics盘中上涨9.07%,报45.595美元/股,成交额9796.98万美元。消息面上,公司于6月22日宣布其候选药物DT120口崩片在治疗重度抑郁症的关键3期EMERGE研究中达成主要终点及所有关键次要疗效终点,显示出统计学显著性和临床意义的改善。随后RBC Capital将目标价从36美元大幅上调至57美元,维持跑赢大盘评级。此外,公司于6月24日完成7亿美元扩大规模包销公开发行定价,每股34美元,募资将用于研发及一般企业用途。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186956929","title":"异动解读|Definium Therapeutics盘中上涨15.48%,核心管线3期研究达成主要终点叠加投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186956929","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186956929?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:00","pubTimestamp":1782309630,"startTime":"0","endTime":"0","summary":"6月24日,Definium Therapeutics盘中上涨15.48%,报42.42美元/股,成交额1.56亿美元。消息面上,公司于6月22日宣布其候选药物DT120口崩片在治疗重度抑郁症的关键3期EMERGE研究中取得积极顶线结果,达成主要终点及所有关键次要疗效终点,显示出与安慰剂相比具有统计学显著性和临床意义的改善,安全性特征与先前研究一致。随后RBC Capital将公司目标价从36美元大幅上调至57美元,维持跑赢大盘评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889615","title":"Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889615","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645889615?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:11","pubTimestamp":1782292315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床后期生物制药公司Definium Therapeutics 正式宣布,其已完成扩大规模的包销公开发行定价,公司将以每股34.00美元的价格公开发行20,588,236股普通股。在不扣除承销折扣、佣金及其他发行费用的情况下,Definium预计此次公开发行的募资总额将达到约7亿美元。本次发行预计将于2026年6月25日左右交割。而就在本次发行定价前不久,Definium刚于6月22日宣布,其用于治疗重度抑郁症的创新疗法“DT120口崩片”在3期临床研究中取得了积极的顶线结果。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UDN","BK4539","BK4007","LENZ","DFTX","UUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109486940","title":"Definium Therapeutics公布DT120口崩片治疗重度抑郁症的3期EMERGE研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109486940","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109486940?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:00","pubTimestamp":1782126018,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布,其针对重度抑郁症(MDD)的候选药物DT120口崩片(ODT)在关键的3期EMERGE研究中取得了积极的顶线结果。该研究达到了其主要终点,显示出与安慰剂相比,在改善抑郁症状方面具有统计学显著性和临床意义的优势。安全性特征与先前研究一致,未发现新的安全问题。这一积极数据为DT120的后续监管申请奠定了坚实基础,标志着公司在精神疾病治疗领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147229029","title":"Definium Therapeutics:DT120口崩片研究达成主要及所有关键次要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1147229029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147229029?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:00","pubTimestamp":1782126016,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布,其候选药物DT120口崩片的一项临床研究,已成功达成预设的主要疗效终点以及所有关键性的次要疗效终点。这一积极结果标志着该药物在目标适应症的开发中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194348262","title":"Definium Therapeutics将于2026年6月22日讨论重度抑郁症III期EMERGE研究的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1194348262","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194348262?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:01","pubTimestamp":1782075697,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布,将于2026年6月22日就其针对重度抑郁症的III期EMERGE研究的顶线结果进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137501338","title":"Definium Therapeutics宣布在DT120 Odt针对重度抑郁症的第二个三期关键研究“Ascend”中完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1137501338","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137501338?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583709,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布,在其针对重度抑郁症的候选药物DT120 Odt的第二个关键性三期临床试验“Ascend”中,已完成对首例患者的给药。这标志着该药物临床开发项目的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180337716","title":"Definium Therapeutics 研发DT120口腔崩解片 针对广泛性焦虑症、重度抑郁症及其他严重脑健康疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1180337716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180337716?lang=zh_cn&edition=full","pubTime":"2026-04-19 07:43","pubTimestamp":1776555796,"startTime":"0","endTime":"0","summary":"Definium Therapeutics公司正在积极推进其核心产品DT120口腔崩解片的研发进程,该药物主要瞄准广泛性焦虑症、重度抑郁症以及其他一系列严重的脑健康疾病的治疗领域。\n这款名为DT120 ODT的创新疗法,展现了公司在精神健康与神经系统疾病治疗方面的前沿探索。其研发策略聚焦于解决当前临床未满足的重大需求,旨在为深受相关疾病困扰的患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100586830","title":"Piper Sandler 首予 Definium Therapeutics 增持评级,目标价49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100586830","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100586830?lang=zh_cn&edition=full","pubTime":"2026-04-10 11:31","pubTimestamp":1775791902,"startTime":"0","endTime":"0","summary":"投资银行 Piper Sandler 宣布,正式开始对生物制药公司 Definium Therapeutics Inc 进行覆盖研究,并给予其“增持”评级。该机构设定了49美元的目标股价,显示出对其未来增长潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101183436","title":"Definium Therapeutics现金储备雄厚:截至2025年底持有4.116亿美元现金及投资,预计可支撑运营至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1101183436","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101183436?lang=zh_cn&edition=full","pubTime":"2026-02-27 05:45","pubTimestamp":1772142302,"startTime":"0","endTime":"0","summary":"生物制药公司Definium Therapeutics(股票代码:DFTX)宣布,截至2025年12月31日,公司持有的现金、现金等价物及投资总额达到4.116亿美元。这一强劲的财务状况预计将为公司的持续运营提供充足资金,支撑其业务发展直至2028年。\n巨额的资金储备为Definium Therapeutics推进其研发管线提供了坚实保障。公司专注于创新疗法的开发,充足的资金使其能够在不依赖额外融资的情况下,持续投入关键研发项目并拓展临床研究。这一财务优势不仅增强了公司的运营稳定性,也为其长期战略目标的实现奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":-0.0153},{"period":"1month","weight":0.7636},{"period":"3month","weight":0.9904},{"period":"6month","weight":1.9061},{"period":"1year","weight":4.4156},{"period":"ytd","weight":2.2599}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Definium Therapeutics, Inc.于2010年根据不列颠哥伦比亚省法律成立。他们是一家处于后期阶段的临床生物制药公司,正在开发新的候选产品来治疗大脑健康障碍。他们的使命是通过将科学的严谨性应用于迷幻药,锻造精神病学的新时代,目标是开发可获得的治疗方法,以大规模解锁愈合。他们正在开发一系列针对神经递质通路的创新候选产品,这些通路在大脑健康疾病中发挥着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.072082},{"month":4,"riseRate":0.8,"avgChangeRate":0.037703},{"month":5,"riseRate":0.5,"avgChangeRate":0.01554},{"month":6,"riseRate":0.5,"avgChangeRate":0.064762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.161014},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}